Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Effect of BIIB014 on the Pharmacokinetics of Rosiglitazone, Warfarin, and Midazolam in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Vipadenant (Primary) ; Midazolam; Rosiglitazone; Warfarin
- Indications Asthma; Parkinson's disease; Thromboembolism; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Biogen Idec
- 23 Nov 2009 New trial record